Arrowstreet Capital Limited Partnership bought a new position in shares of Adaptimmune Therapeutics (NASDAQ:ADAP) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 36,588 shares of the biotechnology company’s stock, valued at approximately $244,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $182,000. Dynamic Technology Lab Private Ltd purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $199,000. Iguana Healthcare Management LLC purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $205,000. California Public Employees Retirement System purchased a new position in Adaptimmune Therapeutics during the 4th quarter worth approximately $287,000. Finally, OxFORD Asset Management LLP grew its stake in Adaptimmune Therapeutics by 30.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock worth $369,000 after buying an additional 10,471 shares during the last quarter. 55.58% of the stock is currently owned by institutional investors and hedge funds.
Shares of ADAP stock traded down $0.42 during midday trading on Friday, hitting $10.42. The company had a trading volume of 607,272 shares, compared to its average volume of 1,004,008. Adaptimmune Therapeutics has a 52-week low of $4.28 and a 52-week high of $13.41. The company has a market capitalization of $1,015.60, a P/E ratio of -13.03 and a beta of 1.19.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Adaptimmune Therapeutics had a negative net margin of 185.39% and a negative return on equity of 32.26%. The company had revenue of $4.27 million during the quarter, compared to analysts’ expectations of $9.38 million. research analysts expect that Adaptimmune Therapeutics will post -0.82 EPS for the current year.
ADAP has been the topic of a number of research reports. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Leerink Swann initiated coverage on Adaptimmune Therapeutics in a research note on Friday, March 16th. They set a “buy” rating and a $15.00 price target on the stock. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 19th. Finally, ValuEngine upgraded Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $11.58.
In related news, major shareholder Ravi Viswanathan bought 104,844 shares of the stock in a transaction on Wednesday, March 21st. The shares were bought at an average cost of $1.81 per share, for a total transaction of $189,767.64. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adrian Rawcliffe sold 600,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total value of $1,026,000.00. The disclosure for this sale can be found here. Insiders acquired a total of 9,385,254 shares of company stock worth $17,966,655 over the last quarter. Company insiders own 24.45% of the company’s stock.
WARNING: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/36588-shares-in-adaptimmune-therapeutics-plc-adap-purchased-by-arrowstreet-capital-limited-partnership.html.
Adaptimmune Therapeutics Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.